Nuwellis receives USPTO notice of patent allowance for CRRT technology

Nuwellis announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office, USPTO, for a patent application related to its innovative pediatric Continuous Renal Replacement Therapy, CRRT, device branded Vivian. This patent strengthens Nuwellis’ intellectual property portfolio and paves the way for the development of novel technology designed to improve treatment options for critically ill children. The patented technology focuses on a design feature that allows healthcare providers to switch seamlessly between stationary operation and “transport” or “ambulation” mode, enabling unprecedented patient mobility. This innovative feature offers unmatched flexibility, allowing clinicians to tailor treatment plans to the specific needs of each young patient.